From hypertransaminasemia to mucopolysaccharidosis IIIA by Paulina Krawiec et al.
ITALIAN JOURNAL
OF PEDIATRICS
Krawiec et al. Italian Journal of Pediatrics 2014, 40:97
http://www.ijponline.net/content/40/1/97CASE REPORT Open AccessFrom hypertransaminasemia to
mucopolysaccharidosis IIIA
Paulina Krawiec1,2*, Elżbieta Pac-Kożuchowska1,2, Beata Mełges1,2, Agnieszka Mroczkowska-Juchkiewicz1,2,
Stanisław Skomra2, Agnieszka Pawłowska-Kamieniak1,2 and Katarzyna Kominek1,2Abstract
Mucopolysaccharidosis type III (MPS III; Sanfilippo syndrome) is a metabolic disorder characterized by the deficiency
of a lysosomal enzyme catalyzing the catabolic pathway of heparan sulphate. MPS III presents with progressive
mental deterioration, speech delay and behavioural problems with subtle somatic features, which can often lead to
misdiagnosis with idiopathic developmental/speech delay, attention deficit/hyperactivity disorder or autism. We
report a case of a 5-year-old boy with developmental delay and behaviour problems admitted to the Department
of Paediatrics due to chronic hypertransaminasemia. The patient developed normally until the age of 2 years when
he was referred to a paediatric neurologist for suspected motor and speech delay. Liver function tests were unexpectedly
found elevated at the age of 3.5 years. Physical examination revealed obesity, mildly coarse facial features and stocky
hands. He showed mental retardation and mild motor delay. The clinical picture strongly suggested mucopolysaccharidosis.
The diagnosis of MPS IIIA was confirmed by decreased activity of heparan
N-sulfatase in leucocytes.
Conclusion: We strongly recommend screening for MPS III in children with severe behavioural abnormalities with
hyperactivity, psychomotor or speech deterioration and failure to achieve early developmental milestones particularly with
facial dysmorphism.
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Mucopolysaccharidosis (MPS) type III, also known as Sanfi-
lippo syndrome, is an autosomal recessive metabolic dis-
order characterized by the deficiency of a lysosomal enzyme
catalyzing the catabolic pathway of glycosaminoglycan
(GAG) - heparan sulfate. Based on the deficiency of a spe-
cific enzyme in the degradation of heparan sulphate, four
different subtypes of MPS III are distinguished, i.e. MPS III
A (heparan N-sulfatase), MPS III B (α-N-acetylglucosamini-
dase), MPS III C (heparan acetyl-CoA: alpha-glucosaminide
N-acetyltransferase) and MPS III D (N-acetylglucosamine 6-
sulfatase) [1,2].
MPS III presents with progressive mental deterioration,
speech delay and behavioural problems with only subtle
somatic features, which can often lead to misdiagnosis with* Correspondence: paulina.krawiec@wp.pl
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unless otherwise stated.idiopathic developmental/speech delay, attention deficit/
hyperactivity disorder (ADHD) or autism spectrum disor-
ders [2].
We report a rare case of a boy with unexpected MPS IIIA
diagnosis to highlight the importance of paediatric history
and physical examination for the diagnostic process and to
indicate that patients with metabolic disorders may develop
any other chronic diseases.
Case report
A 5-year-old boy with developmental delay was admitted
to the hospital for persistent hypertransaminasemia of
18 months’ duration.
The boy was born at term after the uncomplicated preg-
nancy by caesarean section due to the ultrasound con-
firmed large foetus weight and dehiscence of the pubic
symphysis. His birth weight was 4,570 g and birth length
was 59 cm. At the first minute after birth the Apgar score
was 10. No neonatal problems were reported. The boy was
the second child in the family and had the older healthyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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However, his mother had the history of 2 miscarriages in
the first trimester.
According to his parents, the child’s development was
normal until the age of 2 years. Head control was
achieved by the 3rd month of life, sitting without assist-
ance in the 6th month of life and walking in the 9th
month of life. However, he began using single, simple
words (i.e. mum, dad) at the age of 18 months. Toilet
control was achieved at 3 years of age. Since the 2nd year
of life progressive psychomotor developmental delay,
restlessness and impulsivity with hyperactivity became
apparent, therefore he was referred to a paediatric neur-
ologist. About the age of 5 years lack of speech and toi-
let control were noticed.
The clinical history revealed recurrent upper respira-
tory tract infections and recurrent diarrhoea. At present,
his stools are rather constipated. He had adenotomy at
the age of 2 years. Since birth, the boy had the tendency
to excessive weight.Figure 1 Dysmorphic features of our patient. Facial dysmorphism (coar
eyebrows, low set ears, malocclusion, full cheeks, wiry and dry hair and the
hands) seen in our patient.Liver function tests were unexpectedly found to be ele-
vated at the age 3.5 years when he was hospitalized due to
pneumonia. Alanine aminotransferase (ALT) was 144 U/L
(normal <29 U/L) and aspartate aminotransferase (AST)
was 90 U/L (normal <36 U/L). Thereafter, elevated ALT and
AST were observed in follow-up laboratory tests.
On admission to our Department his weight was 36.3 kg
(> > 97th percentile) and height 115 cm (75th percentile).
The Cole’s index was 181.5% and the body mass index was
27.4 kg/m2 (> > 97th percentile).
On physical examination, the boy appeared to have
mildly coarse facial features, the slightly depressed nasal
bridge, prominent eyebrows, low set ears, malocclusion,
full cheeks, wiry and dry hair and the short neck (Figure 1).
The boy had excessive lumbosacral lordosis, genu valga
(knock-knee deformity) and varus feet. He had broad-base
gait with anteversion. His hands were stocky with short
fingers. The liver and the spleen were not palpable.
The boy showed mental retardation and mild motor
delay. His speech was limited to incomprehensiblese facial features, the slightly depressed nasal bridge, prominent
short neck) and skeletal symptoms (genu valga, varus feet, and stocky
Table 1 Laboratory results of our patient
Parameter Result Reference range
ALT [U/L] 144 <29
AST [U/L] 73 <36
Bilirubin [mg/dL] 1.7 1.5
GGT [U/L] 34 <29
CK [U/L] 98 <149
IgG [mg/dL] 521 504-1464
Total cholesterol [mg/dL] 111 <170
Triglyceride [mg/dL] 58 <75
HBs-Antigen Negative Negative
Anti-HCV antibodies Negative Negative
Anti-EBV antibodies Negative Negative
Anti-CMV antibodies Negative Negative
Lysosomal acid lipase [pmol/punch/hr] 0.61 0.37-2.3
α-1-antitrypsin [g/L] 1.3 0.9-2.0
Ceruloplasmin [g/L] 0.3 0.15-0.3
Serum copper [ug/L] 1106 900-1900
24-hour urinary copper [ug/24 h] <10 <60
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behaviour.
The clinical picture strongly suggested mucopolysacchari-
dosis. The daily urinary glycosaminoglycans (GAGs) excre-
tion was 895 mg GAG/g creatinine, i.e. elevated compared
to the normal reference level (<88 mg GAG/g creatinine).
Elevated GAGs were identified as chondroitin sulphate and
heparan sulphate, which suggested mucopolysaccharidosis
III. To confirm the diagnosis and to determine the type of
MPS the lysosomal enzyme activity was assessed in
leucocytes. Heparan N-sulfatase activity was decreased
(1.29 nmol/mg protein/18 h) compared to the normal refer-
ence range (4.1 ± 1.4 nmol/mg protein/18 h). The activities
of other lysosomal enzymes i.e. α-iduronidase, α-N-
acetylglucosaminidase, N-acetyl-transferase, glucosamine
sulfatase, galactosamine sulfatase, β-glucoronidase, arylsul-
fatase and iduronide sulfatase were within normal limits.
The diagnosis of mucopolysaccharydosis III type A was
confirmed.
Moreover, laboratory results revealed hypertransaminase-
mia with slightly elevated γ-glutamyltranspeptydase. De-
tailed diagnostic examinations were performed to determine
the cause of hypertransaminasemia. Based on the serological
tests viral hepatitis caused by hepatitis B virus (HBV), hepa-
titis C virus (HCV), cytomegalovirus (CMV) and Ebstein –
Barr virus (EBV) were excluded. The serum level of creatine
kinase, total immunoglobulin G (IgG), α1-antitrypsin, lyso-
somal acid lipase, ceruloplasmin, copper and 24-hour urin-
ary copper were within the normal range. Thus, muscular
dystrophy, autoimmune hepatitis, α1-antitrypsin deficiency,
lysosomal acid lipase deficiency and Wilson’s disease we
excluded. Table 1 presents the laboratory results of our
patient.
On the abdominal ultrasound examination, the bright
liver echo pattern was found; the liver and spleen were
not enlarged.
Chronic hypertransaminasemia in our patient might
be related to mucopolysaccharidosis or result from coex-
isting non-alcoholic steatohepatitis (NASH). The conclu-
sive diagnostic test should be liver biopsy. However, the
child did not undergo liver biopsy in our department as
he was referred to the Paediatric Metabolic Diseases and
Gastrohepatology Outpatient Clinic.Discussion
In MPS III A the deficiency of heparan N-sulfatase results
in lysosomal accumulation of undegraded heparan sulphate
and eventually in progressive cellular destruction and mul-
tisystemic disease [1,2].
Despite biochemical differences, subtypes of MPS III
are virtually indistinguishable for clinicians. However,
there are data suggesting that the clinical course of MPS
IIIA is more severe, with an earlier onset, more rapidprogression of symptoms and shorter survival than the
other subtypes [1].
The majority of children with MPS IIIA were born
after uneventful pregnancies [1,3]. Buhrman et al. found
that the most common pregnancy complication was cae-
sarean section due to failure to progress, macrocephaly
and breech position, suggesting that the GAGs storage
already occur before birth, which was also found in our
patient’s perinatal history [4].
Interestingly, Meyer et al. noticed a high number of mis-
carriages in mothers of children with MPS IIIA (29%). The
above data need to be interpreted with caution as the inci-
dence of miscarriages is age-dependent and the exact age of
mothers at the time of miscarriage was unknown. However,
further research should be performed to investigate the
risk of miscarriage in pregnancies involving children with
MPS [3].
In general, the early development of a child with MPS
IIIA is normal. Nevertheless, the latest studies of the nat-
ural course of MPS IIIA showed that the initial symptoms
of the disease were present in many patients already dur-
ing the first year of life [3,4]. Furthermore, Meyer et al.
found that three quarters of children with MPS IIIA did
not achieve normal early developmental milestones. In
40.6% of children a delay of speech development (late talk-
ing >15 months) was observed, while only in 7.2 % delay
in motor development (late walking >18 months). In
26.1% of children delay in both speech and motor devel-
opment was noticed [3]. However, the median age at MPS
IIIA diagnosis varied from 3 – 4.5 years [3,4].
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parents in children with MPS were behavioural problems
and sleep disturbances [3]. These findings differ from
those of Buhrman et al. who found that the most common
initial symptom was speech delay (48%), while abnormal
behaviours were observed in 9% of patients [4]. In our pa-
tient the first symptoms which alarmed his parents were
psychomotor progressive retardation and behavioural prob-
lems including restlessness, hyperactivity and impulsivity.
Sleep disturbances were not observed in our patient.
Severe behavioural and sleep problems are well-estab-
lished symptoms of Sanfilippo syndrome. The reported be-
havioural problems include restlessness, severe hyperactivity,
impulsivity, temper tantrums, aggression, unusual affect, i.e.
laughing or crying fits [2,5]. Sleep disturbances are one of
the major concerns in patients with Sanfilippo syndrome, af-
fecting 72 to 96% of patients. The most common sleep
problems include settling difficulties, early waking, nocturnal
waking, and night-time behaviours like chewing bedclothes,
crying, singing or laughing in the night. Some patients show
no circadian rhythm [5].
Somatic symptoms in Sanfilippo syndrome are less overt
than in the other types of MPS. However, there is a growing
body of evidence confirming significant somatic manifest-
ation of MPS IIIA, including coarse facial features, hepato-
megaly, hernia, heart disease, hearing impairment, recurrent
airway infections, persisting diarrhoea, epilepsy and skeletal
abnormalities [3,4,6]. In our patient facial dysmorphism
(coarse facial features, the slightly depressed nasal bridge,
prominent eyebrows, low set ears, malocclusion, full cheeks,
wiry and dry hair and the short neck) and skeletal symptoms
(excessive lumbosacral lordosis, genu valga, and varus feet)
were evident.
In a child with skeletal abnormality imaging findings
may provide a key diagnostic clue. The group of radio-
logical symptoms in mucopolysaccharidosis is known as
dysostosis multiplex and include abnormally shaped
vertebrae and ribs, enlarged skull, spatulate ribs,
hypoplastic epiphyses, thickened diaphyses and bullet-
shaped metacarpals. The other common skeletal symp-
toms are thoracolumbar kyphosis and gibbus deformity,
hip dysplasia and genu valgum [7]. Skeletal abnormal-
ities in Sanfilippo syndrome are less prominent than in
the other types of MPS and tend to appear after neuro-
cognitive manifestations [4,7]. However, regular imaging
of the vertebral column, hips and lower extremities is
recommended for patients with MPS [7]. Unfortunately,
there is no available X-ray of our patient’s skeletal
system.
It should be highlighted that lack of somatic symptoms
including facial dysmorphism, should not exclude the
diagnosis of MPS IIIA [2]. Large variability in the clinical
spectrum of MPS may be a result of residual enzyme ac-
tivity caused by different gene mutations [3]. However,genotype-phenotype correlations remain unclear and need
further investigations [6].
The best to our knowledge chronic hepatitis is not the
established symptom of MPS IIIA. Based on detailed diag-
nostic work-up in our patient, we excluded many possible
causes of chronic hypertransaminasemia i.e. infectious hepa-
titis, muscular dystrophy, autoimmune hepatitis, α1-antitryp-
sin deficiency, lysosomal acid lipase deficiency, and Wilson’s
disease. Chronic hypertransaminasemia and the bright liver
on ultrasound in our patient may suggest non-alcoholic
steatohepatitis (NASH). It may be also related to the liver
storage of glycosaminoglycans. However, such an explan-
ation tends to overlook the fact that in another mucopoly-
saccharidosis – Hunter syndrome (MPS II) – the storage of
glycosaminoglycans in the liver does not lead to its dysfunc-
tion [8]. Unfortunately, to date no research has been focused
on the problem of liver injury in Sanfilippo syndrome.
Nevertheless, liver biopsy is required for definitive diagnosis.
Thus, we referred the child to the Paediatric Metabolic Dis-
eases and Gastrohepatology Outpatient Clinic, The Chil-
dren’s Memorial Health Institute in Warsaw, for further
diagnostic evaluation and treatment.
The present case underlines the importance of holistic
approach to paediatric patient based on thorough med-
ical history and physical examination. It should be noted
that early clinical suspicion is crucial to establish the
diagnosis.
Conclusions
We strongly recommend screening for MPS III in chil-
dren with severe behavioural abnormalities with hyper-
activity, psychomotor or speech deterioration and failure
to achieve early developmental milestones, particularly
with facial dysmorphism. We believe that the present
case report will improve awareness of mucopolysacchari-
dosis in the medical community and result in earlier
diagnosis of MPS.
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